Prognostic and predictive biomarker developments in multiple myeloma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic and predictive biomarker developments in multiple myeloma
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-24
DOI
10.1186/s13045-021-01162-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma
- (2021) Lisa M. Ebert et al. Molecular Oncology
- Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
- (2020) Ioannis V. Kostopoulos et al. Frontiers in Oncology
- Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma
- (2020) Joaquin Martinez-Lopez et al. Blood Advances
- BCMA-targeted immunotherapy for multiple myeloma
- (2020) Bo Yu et al. Journal of Hematology & Oncology
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia
- (2019) Renato Bassan et al. HAEMATOLOGICA
- Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
- (2019) Benjamin G. Barwick et al. Nature Communications
- International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
- (2019) Jens Hillengass et al. LANCET ONCOLOGY
- Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
- (2019) Maria-Victoria Mateos et al. Lancet Haematology
- Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
- (2019) Saad Zafar Usmani et al. Lancet Haematology
- Revisiting NTRKs as an emerging oncogene in hematological malignancies
- (2019) Sunil K. Joshi et al. LEUKEMIA
- Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches
- (2019) Barbara Izzo et al. Frontiers in Oncology
- Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
- (2019) Ilaria Del Giudice et al. Frontiers in Oncology
- Sphingolipids and the unfolded protein response
- (2019) Melissa K. Bennett et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
- (2019) Hervé Avet-Loiseau et al. Clinical Lymphoma Myeloma & Leukemia
- Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
- (2019) Bruno Paiva et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to proteasome inhibitors and other targeted therapies in myeloma
- (2018) Craig T. Wallington-Beddoe et al. BRITISH JOURNAL OF HAEMATOLOGY
- Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma
- (2018) Sridurga Mithraprabhu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing
- (2018) Guangwu Guo et al. LEUKEMIA
- A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
- (2018) Brian A. Walker et al. LEUKEMIA
- Targeting MYC in multiple myeloma
- (2018) K. K. Jovanović et al. LEUKEMIA
- Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
- (2018) Charlotte Pawlyn et al. LEUKEMIA
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma
- (2018) S. Manier et al. Nature Communications
- Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
- (2018) Arjun Lakshman et al. Blood Cancer Journal
- Promise of Immune Therapies in Multiple Myeloma
- (2018) Kenneth C. Anderson Journal of Oncology Practice
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
- (2018) Aurore Perrot et al. BLOOD
- Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA
- (2018) Giulia Biancon et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
- (2018) Graham H Jackson et al. LANCET ONCOLOGY
- Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)
- (2018) L. Sanoja-Flores et al. Blood Cancer Journal
- Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
- (2017) Anna Oberle et al. HAEMATOLOGICA
- Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
- (2017) Juan-Jose Lahuerta et al. JOURNAL OF CLINICAL ONCOLOGY
- Proteomic characterization of human multiple myeloma bone marrow extracellular matrix
- (2017) S V Glavey et al. LEUKEMIA
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
- (2017) J Flores-Montero et al. LEUKEMIA
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
- (2017) Janet Woodcock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates
- (2017) Olena Kis et al. Nature Communications
- Current applications of multiparameter flow cytometry in plasma cell disorders
- (2017) T Jelinek et al. Blood Cancer Journal
- Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group
- (2017) J Hillengass et al. Blood Cancer Journal
- The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma
- (2017) Yuji Mishima et al. Cell Reports
- Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
- (2017) Anna Oberle et al. HAEMATOLOGICA
- Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma
- (2017) Nikhil C. Munshi et al. JAMA Oncology
- MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma
- (2016) Y.-W. Qiang et al. BLOOD
- Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
- (2016) K. M. Kortum et al. BLOOD
- The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma
- (2016) C. Pawlyn et al. CLINICAL CANCER RESEARCH
- Gene Expression Profiles in Myeloma: Ready for the Real World?
- (2016) Raphael Szalat et al. CLINICAL CANCER RESEARCH
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- (2016) Michael Ghermezi et al. HAEMATOLOGICA
- Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents
- (2016) Paola Tacchetti et al. HAEMATOLOGICA
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens
- (2016) Paola Tacchetti et al. LEUKEMIA & LYMPHOMA
- Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
- (2016) E. A. Punnoose et al. MOLECULAR CANCER THERAPEUTICS
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic interrogation of circulating multiple myeloma cells at single-cell resolution
- (2016) J. G. Lohr et al. Science Translational Medicine
- Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era
- (2016) R Chakraborty et al. Blood Cancer Journal
- Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy
- (2016) Dominik Dytfeld et al. Oncotarget
- Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia
- (2016) Alexey Zatula et al. Oncotarget
- Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
- (2016) Young Kwang Chae et al. Oncotarget
- Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma
- (2016) Shang-Yi Huang et al. Oncotarget
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- (2016) Michael Ghermezi et al. HAEMATOLOGICA
- Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents
- (2016) Paola Tacchetti et al. HAEMATOLOGICA
- Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
- (2015) M.-L. Chretien et al. BLOOD
- Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens
- (2015) Dominik Dytfeld et al. BRITISH JOURNAL OF HAEMATOLOGY
- PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma
- (2015) E. Zamagni et al. CLINICAL CANCER RESEARCH
- Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma
- (2015) Kevin Barley et al. Clinical Lymphoma Myeloma & Leukemia
- Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation
- (2015) Christof Scheid et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement
- (2015) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
- (2015) Brian A. Walker et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple myeloma
- (2015) Christoph Röllig et al. LANCET
- Inhibiting MEK in MAPK pathway-activated myeloma
- (2015) C J Heuck et al. LEUKEMIA
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
- (2015) C C Bjorklund et al. Blood Cancer Journal
- Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
- (2015) T Vu et al. Blood Cancer Journal
- Deep Response in Multiple Myeloma: A Critical Review
- (2015) Mariateresa Fulciniti et al. Biomed Research International
- Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma
- (2015) Zhigang Xie et al. Oncotarget
- Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome
- (2014) A. Brioli et al. BLOOD
- Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
- (2014) Y. X. Zhu et al. BLOOD
- Quantification of clonal circulating plasma cells in relapsed multiple myeloma
- (2014) Wilson I. Gonsalves et al. BRITISH JOURNAL OF HAEMATOLOGY
- Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
- (2014) Jens G. Lohr et al. CANCER CELL
- Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy
- (2014) C. G. Patel et al. CLINICAL CANCER RESEARCH
- State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings
- (2014) Charles Mesguich et al. EUROPEAN JOURNAL OF RADIOLOGY
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma
- (2014) W I Gonsalves et al. LEUKEMIA
- Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
- (2013) Anita K. Gandhi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
- (2013) A Thakurta et al. LEUKEMIA
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
- (2013) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the BRAF V600E Mutation in Multiple Myeloma
- (2013) M. Andrulis et al. Cancer Discovery
- Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
- (2012) S. Kumar et al. BLOOD
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Metabolic Tumor Volume Assessed by 18F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma
- (2012) R. Fonti et al. JOURNAL OF NUCLEAR MEDICINE
- A gene expression signature for high-risk multiple myeloma
- (2012) R Kuiper et al. LEUKEMIA
- The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
- (2012) A Kalff et al. Blood Cancer Journal
- Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
- (2011) N. C. Munshi et al. BLOOD
- Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
- (2011) E. Zamagni et al. BLOOD
- Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival
- (2011) K. D. Boyd et al. CLINICAL CANCER RESEARCH
- Initial genome sequencing and analysis of multiple myeloma
- (2011) Michael A. Chapman et al. NATURE
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome
- (2010) N. J. Dickens et al. CLINICAL CANCER RESEARCH
- Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
- (2010) D. Hose et al. HAEMATOLOGICA
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
- (2010) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma
- (2010) Jens Hillengass et al. JOURNAL OF CLINICAL ONCOLOGY
- Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
- (2010) Marco Ladetto et al. JOURNAL OF CLINICAL ONCOLOGY
- The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group
- (2010) E Terpos et al. LEUKEMIA
- Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma
- (2010) S Kumar et al. LEUKEMIA
- What are biomarkers?
- (2010) Kyle Strimbu et al. Current Opinion in HIV and AIDS
- Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma
- (2009) L. Chen et al. BLOOD
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
- (2009) R Fonseca et al. LEUKEMIA
- The clinical significance of soluble human leukocyte antitgen class-I, ICTP, and RANKL molecules in multiple myeloma patients
- (2008) Philipp Schütt et al. HUMAN IMMUNOLOGY
- Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome
- (2008) Olivier Decaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma
- (2008) C Jakob et al. LEUKEMIA
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
- (2007) A. Dispenzieri et al. BLOOD
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started